The drugmakers’ shares were down by 18 percent on six times the normal trading volume, which prompted the company to release a statement saying it doesn’t have information that would explain the drop.
On Sept. 13, Catalyst’s stocks fell 17 percent after announcing plans to sell 8 million shares to generate capital to buy or license other medicines.
Last year, the drugmaker came under fire after it received orphan status for its $375,000 drug, Firdapse, which made a free alternative unavailable to patients.
More articles on pharmacy:
World Pharmacist Day promotes use of safe and effective medicines
USP delays release of updated compounding standards
Americans pay up to 67 times more for drugs than other countries
